{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:41:05Z","timestamp":1790995265925,"version":"4.1.0"},"reference-count":59,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,1,28]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                  <jats:title>Importance<\/jats:title>\n                  <jats:p>Distinguishing type 2 (T2MI) from type 1 myocardial infarction (T1MI) in clinical practice can be difficult, and the management and prognosis for T2MI remain uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To compare precipitating factors, risk factors, investigations, management and outcomes for T2MI and T1MI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data sources<\/jats:title>\n                  <jats:p>Medline and Embase databases as well as reference list of recent articles were searched January 2009 to December 2020 for term \u2018type 2 myocardial infarction\u2019.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study selection<\/jats:title>\n                  <jats:p>Studies were included if they used a universal definition of MI and reported quantitative data on at least one variable of interest.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data extraction and synthesis<\/jats:title>\n                  <jats:p>Data were pooled using random-effect meta-analysis. Risk of bias was assessed using Newcastle-Ottawa quality assessment tool. Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were followed. All review stages were conducted by two reviewers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcomes and measures<\/jats:title>\n                  <jats:p>Risk factors, presenting symptoms, cardiac investigations such as troponin and angiogram, management and outcomes such as mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>40 cohort studies comprising 98 930 patients with T1MI and 13 803 patients with T2MI were included. Compared with T1MI, patients with T2MI were: more likely to have pre-existing chronic kidney disease (OR 1.87; 95% CI 1.53 to 2.28) and chronic heart failure (OR 2.35; 95% CI 1.82 to 3.03), less likely to present with typical cardiac symptoms of chest pain (OR 0.19; 95% CI 0.13 to 0.26) and more likely to present with dyspnoea (OR 2.64; 95% CI 1.86 to 3.74); more likely to demonstrate non-specific ST-T wave changes on ECG (OR 2.62; 95% CI 1.81 to 3.79) and less likely to show ST elevation (OR 0.22; 95% CI 0.17 to 0.28); less likely to undergo coronary angiography (OR 0.09; 95% CI 0.06 to 0.12) and percutaneous coronary intervention (OR 0.06; 95% CI 0.04 to 0.10) or receive cardioprotective medications, such as statins (OR 0.25; 95% CI 0.16 to 0.38) and beta-blockers (OR 0.45; 95% CI 0.33 to 0.63). T2MI had greater risk of all cause 1-year mortality (OR 3.11; 95% CI 1.91 to 5.08), with no differences in short-term mortality (OR 1.34; 95% CI 0.63 to 2.85).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion and relevance<\/jats:title>\n                  <jats:p>This review has identified clinical, management and survival differences between T2MI and T1MI with greater precision and scope than previously reported. Differential use of coronary revascularisation and cardioprotective medications highlight ongoing uncertainty of their utility in T2MI compared with T1MI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-055755","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T11:46:44Z","timestamp":1645098404000},"page":"e055755","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Diagnostic features, management and prognosis of type 2 myocardial infarction compared to type 1 myocardial infarction: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0129-8297","authenticated-orcid":false,"given":"Kyle","family":"White","sequence":"first","affiliation":[{"name":"Internal Medicine and Clinical Epidemiology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia"},{"name":"School of Clinical Medicine, University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansey","family":"Kinarivala","sequence":"additional","affiliation":[{"name":"Internal Medicine and Clinical Epidemiology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7596-0837","authenticated-orcid":false,"given":"Ian","family":"Scott","sequence":"additional","affiliation":[{"name":"Internal Medicine and Clinical Epidemiology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia"},{"name":"School of Clinical Medicine, University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"2025101812562017000_12.2.e055755.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.187397"},{"key":"2025101812562017000_12.2.e055755.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31826e1058"},{"key":"2025101812562017000_12.2.e055755.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.08.1038"},{"key":"2025101812562017000_12.2.e055755.4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2016.04.045","article-title":"Chest pain, dyspnea and other symptoms in patients with type 1 and 2 myocardial infarction. A literature review","volume":"215","author":"Lippi","year":"2016","journal-title":"Int J Cardiol"},{"key":"2025101812562017000_12.2.e055755.5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1515\/cclm-2016-0324","article-title":"Cardiac troponins and mortality in type 1 and 2 myocardial infarction","volume":"55","author":"Lippi","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"2025101812562017000_12.2.e055755.6","doi-asserted-by":"crossref","first-page":"348","DOI":"10.21037\/cdt.2017.03.21","article-title":"Type 2 versus type 1 myocardial infarction: a comparison of clinical characteristics and outcomes with a meta-analysis of observational studies","volume":"7","author":"Gupta","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"key":"2025101812562017000_12.2.e055755.7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.cjco.2020.02.005","article-title":"Meta-Analysis comparing outcomes of type 2 myocardial infarction and type 1 myocardial infarction with a focus on dual antiplatelet therapy","volume":"2","author":"Reid","year":"2020","journal-title":"CJC Open"},{"key":"2025101812562017000_12.2.e055755.8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/clc.23230","article-title":"A systematic review on the triggers and clinical features of type 2 myocardial infarction","volume":"42","author":"Wang","year":"2019","journal-title":"Clin Cardiol"},{"key":"2025101812562017000_12.2.e055755.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2025101812562017000_12.2.e055755.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d549"},{"key":"2025101812562017000_12.2.e055755.11","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"2025101812562017000_12.2.e055755.12","unstructured":"Wells BS, D GA , O'Connell JP , Welch V , et al . The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses: Ottawa Hospital research Institute, 2011. Available: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"2025101812562017000_12.2.e055755.13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008661"},{"key":"2025101812562017000_12.2.e055755.14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2020.04.050","article-title":"Acute myocardial infarction in a high-risk cancer population: outcomes following conservative versus invasive management","volume":"313","author":"Balanescu","year":"2020","journal-title":"Int J Cardiol"},{"key":"2025101812562017000_12.2.e055755.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.11.035"},{"key":"2025101812562017000_12.2.e055755.16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.041160"},{"key":"2025101812562017000_12.2.e055755.17","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-310243"},{"key":"2025101812562017000_12.2.e055755.18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042960"},{"key":"2025101812562017000_12.2.e055755.19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.031806"},{"key":"2025101812562017000_12.2.e055755.20","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1515\/cclm-2017-0609","article-title":"No additional value of conventional and high-sensitivity cardiac troponin over clinical scoring systems in the differential diagnosis of type 1 vs. type 2 myocardial infarction","volume":"56","author":"Consuegra-S\u00e1nchez","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"2025101812562017000_12.2.e055755.21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4236\/wjcd.2012.24039","article-title":"Prognostic implications of type 2 myocardial infarctions","volume":"02","author":"El-Haddad","year":"2012","journal-title":"World J Cardiovasc Dis"},{"key":"2025101812562017000_12.2.e055755.22","first-page":"41","article-title":"Type-Ii myocardial infarction and chronic myocardial injury rates, invasive management, and 4-year mortality among consecutive patients undergoing high-sensitivity troponin T testing in the emergency department","volume":"6","author":"Etaher","year":"2020","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2025101812562017000_12.2.e055755.23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017404","article-title":"Type 2 myocardial infarction in general medical wards: clinical features, treatment, and prognosis in comparison with type 1 myocardial infarction","volume":"98","author":"Furie","year":"2019","journal-title":"Medicine"},{"key":"2025101812562017000_12.2.e055755.24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ahj.2017.10.007","article-title":"Clinical features and outcomes of patients with type 2 myocardial infarction: insights from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (tracer) trial","volume":"196","author":"Guimar\u00e3es","year":"2018","journal-title":"Am Heart J"},{"key":"2025101812562017000_12.2.e055755.25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.carrev.2019.04.009","article-title":"Implications of misclassification of type 2 myocardial infarction on clinical outcomes","volume":"21","author":"Hawatmeh","year":"2020","journal-title":"Cardiovasc Revasc Med"},{"key":"2025101812562017000_12.2.e055755.26","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s00380-019-01350-z","article-title":"Higher non-cardiac mortality and lesser impact of early revascularization in patients with type 2 compared to type 1 acute myocardial infarction: results from the Tokyo CCU network registry","volume":"34","author":"Higuchi","year":"2019","journal-title":"Heart Vessels"},{"key":"2025101812562017000_12.2.e055755.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.03.003"},{"key":"2025101812562017000_12.2.e055755.28","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2019-315036"},{"key":"2025101812562017000_12.2.e055755.29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.amjmed.2017.11.043","article-title":"Different causes of death in patients with myocardial infarction type 1, type 2, and myocardial injury","volume":"131","author":"Lambrecht","year":"2018","journal-title":"Am J Med"},{"key":"2025101812562017000_12.2.e055755.30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jjcc.2015.04.001","article-title":"Type 2 myocardial infarction: a descriptive analysis and comparison with type 1 myocardial infarction","volume":"67","author":"Landes","year":"2016","journal-title":"J Cardiol"},{"key":"2025101812562017000_12.2.e055755.31","first-page":"15","article-title":"Comparison between type-2 and type-1 myocardial infarction: clinical features, treatment strategies and outcomes","volume":"13","author":"L\u00f3pez-Cuenca","year":"2016","journal-title":"J Geriatr Cardiol"},{"key":"2025101812562017000_12.2.e055755.32","doi-asserted-by":"publisher","DOI":"10.1111\/acem.13033"},{"key":"2025101812562017000_12.2.e055755.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.07.774"},{"key":"2025101812562017000_12.2.e055755.34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx457"},{"key":"2025101812562017000_12.2.e055755.35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000371739","article-title":"Universal definition of myocardial infarction: clinical insights","volume":"131","author":"Paiva","year":"2015","journal-title":"Cardiology"},{"key":"2025101812562017000_12.2.e055755.36","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.amjmed.2020.02.024","article-title":"A comparison of biomarker rise in type 1 and type 2 myocardial infarction","volume":"133","author":"Pandey","year":"2020","journal-title":"Am J Med"},{"key":"2025101812562017000_12.2.e055755.37","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.amjmed.2018.04.032","article-title":"Short-Term prognosis of myocardial injury, type 1, and type 2 myocardial infarction in the emergency unit","volume":"131","author":"Putot","year":"2018","journal-title":"Am J Med"},{"key":"2025101812562017000_12.2.e055755.38","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3390\/jcm8122100","article-title":"Type 1 or type 2 myocardial infarction in patients with a history of coronary artery disease: data from the emergency department","volume":"8","author":"Putot","year":"2019","journal-title":"J Clin Med"},{"key":"2025101812562017000_12.2.e055755.39","doi-asserted-by":"crossref","first-page":"108","DOI":"10.14336\/AD.2019.0405","article-title":"Type 2 myocardial infarction: a geriatric population-based model of pathogenesis","volume":"11","author":"Putot","year":"2020","journal-title":"Aging Dis"},{"key":"2025101812562017000_12.2.e055755.40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2459\/JCM.0000000000000504","article-title":"Type 2 myocardial infarction: incidence, presentation, treatment and outcome in routine clinical practice","volume":"18","author":"Radovanovic","year":"2017","journal-title":"J Cardiovasc Med"},{"key":"2025101812562017000_12.2.e055755.41","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.043100"},{"key":"2025101812562017000_12.2.e055755.42","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005672"},{"key":"2025101812562017000_12.2.e055755.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.12.020"},{"key":"2025101812562017000_12.2.e055755.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.02.029"},{"key":"2025101812562017000_12.2.e055755.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.05.049"},{"key":"2025101812562017000_12.2.e055755.46","doi-asserted-by":"publisher","DOI":"10.1177\/2048872614538411"},{"key":"2025101812562017000_12.2.e055755.47","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9061686","article-title":"Long-Term prognosis of patients with myocardial infarction type 1 and type 2 with and without involvement of coronary vasospasm","volume":"9","author":"Sato","year":"2020","journal-title":"J Clin Med"},{"key":"2025101812562017000_12.2.e055755.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.10.056"},{"key":"2025101812562017000_12.2.e055755.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.12.052"},{"key":"2025101812562017000_12.2.e055755.50","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000000545"},{"key":"2025101812562017000_12.2.e055755.51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084285"},{"key":"2025101812562017000_12.2.e055755.52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/ACCJ.ACCJ_30_20","article-title":"Mortality and morbidity associated with type 2 myocardial infarction: a single-center study","volume":"2","author":"Truong","year":"2020","journal-title":"Annals of Clinical Cardiology"},{"key":"2025101812562017000_12.2.e055755.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.09.031"},{"key":"2025101812562017000_12.2.e055755.54","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.023052"},{"key":"2025101812562017000_12.2.e055755.55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ahj.2018.09.016","article-title":"The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (Act-2): a randomized trial design","volume":"208","author":"Lambrakis","year":"2019","journal-title":"Am Heart J"},{"key":"2025101812562017000_12.2.e055755.56","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1093\/eurheartj\/ehaa035","article-title":"Clinical application of the 4th universal definition of myocardial infarction","volume":"41","author":"Hartikainen","year":"2020","journal-title":"Eur Heart J"},{"key":"2025101812562017000_12.2.e055755.57","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13643-017-0644-y","article-title":"Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study","volume":"6","author":"Bramer","year":"2017","journal-title":"Syst Rev"},{"key":"2025101812562017000_12.2.e055755.58","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300129"},{"key":"2025101812562017000_12.2.e055755.59","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jacc.2020.12.034","article-title":"Patient characteristics and clinical outcomes of type 1 versus type 2 myocardial infarction","volume":"77","author":"McCarthy","year":"2021","journal-title":"J Am Coll Cardiol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-055755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:56:30Z","timestamp":1760817390000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-055755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,17]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/bmjopen-2021-055755"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-055755","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}